At a glance
ClinicalIndex Comparison RecordN/ACompleted· 33 enrolled
Drug / intervention
Sérum VERRUPROdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Multicentric, Before After Study to Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts.
Swiss Footcare Laboratories - Poderm Professional·interventional·Posted Jan 19, 2024·Updated Mar 5, 2025
In Brief
A clinical study evaluating Sérum VERRUPRO for Warts and 2 related conditions. Completed, enrolled 33 participants across 2 sites.
Detailed Summary
The principal aim of this study is to evaluate the efficacy and the safety of the tested product on common and plantar wart after 35 days of treatment. For this study, 33 patients presenting at least one common wart on the fingers, back on the hand or a plantar wart of a size between 0.1 and 0.5cm and present since less than 6 months will be included to reach this objective
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWarts, Plantar Wart, Common Wart
CountriesTunisia
Collaborators--
Timeline
N/ACompletedFinished
202420252026
First PostedJan 2024
Enrollment StartFeb 2024
Primary CompletionAug 2024
TodayJul 2026
First PostedJan 19, 2024
Enrollment StartFeb 19, 2024
Primary CompletionAug 20, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.5 years ago
Interventions
Sérum VERRUPROdevice
To be applied twice a day